The Economic Power of Orphan Drugs
Despite the smaller patient pool for rare disease R&D, the economics of orphan drug development shows great potential for commercialization.
Newport Biologics White Paper
What you need to know about the follow-on biologic market in the U.S.: Implications, strategies, and impact
Newport Deals White Paper
Gaining market share in the generic drug industry through acquisitions and partnerships.
An Outlook on US Biosimilar Competition
Provides updates and changes associated with biosimilar regulations in the US. Additionally, the paper will identify requirements for success, and the likely early
entrants in the US market.
CordenPharma Case Study
Newport Premium™ (For Generics) helps CordenPharma stand out from its competitors and establish a global brand in the generic and contract manufacturing market.
SK Chemicals Case Study
Newport Premium™ (For Generics ) helps SK Chemicals stand out from its competitors and establish a global brand in the Bio-Pharmaceutical market.
Brazil’s Institute for Applied Economic Research (IPEA ) Case Study
Newport® proves to be a vital tool for Generic information, business development and global API sourcing intelligence.
Farmabios Case Study
Newport Premium™ (For Generics) proves to be a vital too l in fast, smart decision making for an API business professional across competitive intelligence, target data, and customers.
Newport Premium Testimonial - Global API Manufacturer
How comprehensive scientific and competitive data helps drive growth at a leading global API manufacturer
Is API manufacturing returning to Europe
Article by Shannon Bennett, Pharmaceutical Research Analyst, Published in Speciality Chemicals Magazine, June 2012
With Biosimilars: Stick to Your Strengths
Article by Andrew Bourgoin, Senior Pharmaceutical Research Analyst – Biologics, Published in CHEManager, September 25, 2012
Will API Manufacturing Move out of India and China?
Article by Molly Bowman, Manager Industry Research, Published in CHEManager Europe | April 2012
First to File and Beyond: Paragraph IV Business Strategies
Webinar by Benjamin Burck, Project Manager & Analyst | March 2012
A Smart Target for Generics?
Article by Michael Glessner, Pharmaceutical Research Analyst, Published in CHEManager Europe | No. 11/2012
China increases its actvity in regulated markets
Article by Bob Kennedy, Newport Research Manager, Published in Pharma China | July 2012
Antibiotics — Will Changes to Eastern Regulations Impact the West?
Article by Emily Kimball, Pharmaceutical Research Analyst, Published in CHEManager Europe | No. 6/2012
Trends in Pharmaceutical Outsourcing
Article by Kate Kuhrt, Senior Director of Generics and Content Strategy, CHEManager Europe | July 19, 2012
Read more articles by Thomson Reuters Generics and API Experts